

Senator Todd Weiler proposes the following substitute bill:

PHARMACIST DISPENSING AUTHORITY AMENDMENTS

2018 GENERAL SESSION

STATE OF UTAH

Chief Sponsor: Todd Weiler

House Sponsor: _____

LONG TITLE

General Description:

This bill permits a pharmacist to dispense a self-administered hormonal contraceptive under a standing prescription drug order.

Highlighted Provisions:

This bill:

- ▶ authorizes the use of a standing prescription drug order issued by a physician to dispense a self-administered hormonal contraceptive;
- ▶ creates standards and procedures that a pharmacist must follow when prescribing a self-administered hormonal contraceptive;
- ▶ limits liability for physicians who issue a standing prescription drug order for a self-administered hormonal contraceptive; and
- ▶ specifies that the prescribing or dispensing of a self-administered hormonal contraceptive by a pharmacist is not unprofessional or unlawful conduct.

Money Appropriated in this Bill:

None

Other Special Clauses:

None

Utah Code Sections Affected:



26 AMENDS:

27 [58-17b-102](#), as last amended by Laws of Utah 2015, Chapter 336

28 [58-17b-501](#), as last amended by Laws of Utah 2017, Chapter 392

29 [58-17b-502](#), as last amended by Laws of Utah 2016, Chapter 405

30 ENACTS:

31 [26-62-101](#), Utah Code Annotated 1953

32 [26-62-102](#), Utah Code Annotated 1953

33 [26-62-103](#), Utah Code Annotated 1953

34 [26-62-104](#), Utah Code Annotated 1953

35 [26-62-105](#), Utah Code Annotated 1953

36 [26-62-106](#), Utah Code Annotated 1953

37 [26-62-107](#), Utah Code Annotated 1953



39 *Be it enacted by the Legislature of the state of Utah:*

40 Section 1. Section [26-62-101](#) is enacted to read:

41 **CHAPTER 62. FAMILY PLANNING ACCESS ACT**

42 **[26-62-101](#). Title.**

43 This chapter is known as the "Family Planning Access Act."

44 Section 2. Section [26-62-102](#) is enacted to read:

45 **[26-62-102](#). Definitions.**

46 As used in this chapter:

47 (1) "Dispense" means the same as that term is defined in Section [58-17b-102](#).

48 (2) "Local health department" means:

49 (a) a local health department, as defined in Section [26A-1-102](#); or

50 (b) a multicounty local health department, as defined in Section [26A-1-102](#).

51 (3) "Patient counseling" means the same as that term is defined in Section [58-17b-102](#).

52 (4) "Pharmacist" means the same as that term is defined in Section [58-17b-102](#).

53 (5) "Pharmacy intern" means the same as that term is defined in Section [58-17b-102](#).

54 (6) "Physician" means the same as that term is defined in Section [58-67-102](#).

55 (7) "Prescribe" means the same as that term is defined in Section [58-17b-102](#).

56 (8) (a) "Self-administered hormonal contraceptive" means a self-administered

57 hormonal contraceptive that is approved by the United States Food and Drug Administration to
58 prevent pregnancy.

59 (b) "Self-administered hormonal contraceptive" includes an oral hormonal
60 contraceptive, a hormonal vaginal ring, and a hormonal contraceptive patch.

61 (c) "Self-administered hormonal contraceptive" does not include any drug intended to
62 induce an abortion, as that term is defined in Section [76-7-301](#).

63 Section 3. Section **26-62-103** is enacted to read:

64 **26-62-103. Voluntary participation.**

65 This chapter does not create a duty or standard of care for a person to prescribe or
66 dispense a self-administered hormonal contraceptive.

67 Section 4. Section **26-62-104** is enacted to read:

68 **26-62-104. Authorization to dispense self-administered hormonal contraceptives.**

69 Notwithstanding Title 58, Chapter 17b, Pharmacy Practice Act, a person licensed under
70 Title 58, Chapter 17b, Pharmacy Practice Act, to dispense a self-administered hormonal
71 contraceptive may dispense the self-administered hormonal contraceptive:

72 (1) pursuant to a standing prescription drug order made in accordance with Section
73 [26-62-105](#);

74 (2) without any other prescription drug order from a person licensed to prescribe a
75 self-administered hormonal contraceptive; and

76 (3) in accordance with the dispensing guidelines in Section [26-62-106](#).

77 Section 5. Section **26-62-105** is enacted to read:

78 **26-62-105. Standing prescription drug orders for a self-administered hormonal**
79 **contraceptive.**

80 A physician who is licensed to prescribe a self-administered hormonal contraceptive,
81 including a physician acting in the physician's capacity as an employee of the department, or a
82 medical director of a local health department, may issue a standing prescription drug order
83 authorizing the dispensing of the self-administered hormonal contraceptive under Section
84 [26-62-104](#) in accordance with a protocol that:

85 (1) requires the physician to specify the persons, by professional license number,
86 authorized to dispense the self-administered hormonal contraceptive;

87 (2) requires the physician to review at least annually the dispensing practices of those

88 authorized by the physician to dispense the self-administered hormonal contraceptive;
89 (3) requires those authorized by the physician to dispense the self-administered
90 hormonal contraceptive to make and retain a record of each person to whom the
91 self-administered hormonal contraceptive is dispensed, including:
92 (a) the name of the person;
93 (b) the drug dispensed; and
94 (c) other relevant information; and
95 (4) is approved by the Division of Occupational and Professional Licensing within the
96 Department of Commerce by administrative rule made in accordance with Title 63G, Chapter
97 3, Utah Administrative Rulemaking Act.

98 Section 6. Section **26-62-106** is enacted to read:

99 **26-62-106. Guidelines for dispensing a self-administered hormonal contraceptive.**

100 (1) A pharmacist or pharmacist intern who dispenses a self-administered hormonal
101 contraceptive under this chapter:
102 (a) shall obtain a completed self-screening risk assessment questionnaire approved by
103 the Board of Pharmacy and the Physicians Licensing Board from the patient before dispensing
104 the self-administered hormonal contraceptive;
105 (b) if the results of the evaluation in Subsection (1)(a) indicate that it is unsafe to
106 dispense a self-administered hormonal contraceptive to a patient:
107 (i) may not dispense a self-administered hormonal contraceptive to the patient; and
108 (ii) shall refer the patient to a primary care or women's health care practitioner;
109 (c) may not continue to dispense a self-administered hormonal contraceptive to a
110 patient for more than 24 months after the date of the initial prescription without evidence that
111 the patient has consulted with a primary care or women's health care practitioner during the
112 preceding 24 months; and
113 (d) shall provide the patient with:
114 (i) written information regarding:
115 (A) the importance of seeing the patient's primary care practitioner or women's health
116 care practitioner to obtain recommended tests and screening; and
117 (B) the effectiveness and availability of long-acting reversible contraceptives as an
118 alternative to self-administered hormonal contraceptives; and

119 (ii) a copy of the record of the encounter with the patient that includes:
120 (A) the patient's completed self-assessment tool; and
121 (B) a description of the contraceptives dispensed, or the basis for not dispensing a
122 contraceptive.

123 (2) If a pharmacist dispenses a self-administered hormonal contraceptive to a patient,
124 the pharmacist shall, at a minimum, provide patient counseling to the patient regarding:

125 (a) the appropriate administration and storage of the self-administered hormonal
126 contraceptive;

127 (b) potential side effects and risks of the self-administered hormonal contraceptive;

128 (c) the need for backup contraception;

129 (d) when to seek emergency medical attention; and

130 (e) the risk of contracting a sexually transmitted infection or disease, and ways to
131 reduce the risk of contraction.

132 (3) (a) The board shall make rules in accordance with Title 63G, Chapter 3, Utah 601
133 Administrative Rulemaking Act, establishing the self-screening risk assessment questionnaire
134 described in Subsection (1)(a).

135 (b) When making rules under this Subsection (3), the board shall seek
136 recommendations from the department and the Physicians Licensing Board.

137 Section 7. Section **26-62-107** is enacted to read:

138 **26-62-107. Limited civil liability.**

139 A physician who issues a standing prescription drug order in accordance with Section
140 26-62-105 is not liable for any civil damages for acts or omissions resulting from the
141 dispensing of a self-administered hormonal contraceptive under this chapter.

142 Section 8. Section **58-17b-102** is amended to read:

143 **58-17b-102. Definitions.**

144 In addition to the definitions in Section **58-1-102**, as used in this chapter:

145 (1) "Administering" means:

146 (a) the direct application of a prescription drug or device, whether by injection,
147 inhalation, ingestion, or by any other means, to the body of a human patient or research subject
148 by another person; or

149 (b) the placement by a veterinarian with the owner or caretaker of an animal or group

150 of animals of a prescription drug for the purpose of injection, inhalation, ingestion, or any other
151 means directed to the body of the animal by the owner or caretaker in accordance with written
152 or verbal directions of the veterinarian.

153 (2) "Adulterated drug or device" means a drug or device considered adulterated under
154 21 U.S.C. Sec. 351 (2003).

155 (3) (a) "Analytical laboratory" means a facility in possession of prescription drugs for
156 the purpose of analysis.

157 (b) "Analytical laboratory" does not include a laboratory possessing prescription drugs
158 used as standards and controls in performing drug monitoring or drug screening analysis if the
159 prescription drugs are prediluted in a human or animal body fluid, human or animal body fluid
160 components, organic solvents, or inorganic buffers at a concentration not exceeding one
161 milligram per milliliter when labeled or otherwise designated as being for in vitro diagnostic
162 use.

163 (4) "Animal euthanasia agency" means an agency performing euthanasia on animals by
164 the use of prescription drugs.

165 (5) "Automated pharmacy systems" includes mechanical systems which perform
166 operations or activities, other than compounding or administration, relative to the storage,
167 packaging, dispensing, or distribution of medications, and which collect, control, and maintain
168 all transaction information.

169 (6) "Beyond use date" means the date determined by a pharmacist and placed on a
170 prescription label at the time of dispensing that indicates to the patient or caregiver a time
171 beyond which the contents of the prescription are not recommended to be used.

172 (7) "Board of pharmacy" or "board" means the Utah State Board of Pharmacy created
173 in Section [58-17b-201](#).

174 (8) "Branch pharmacy" means a pharmacy or other facility in a rural or medically
175 underserved area, used for the storage and dispensing of prescription drugs, which is dependent
176 upon, stocked by, and supervised by a pharmacist in another licensed pharmacy designated and
177 approved by the division as the parent pharmacy.

178 (9) "Centralized prescription processing" means the processing by a pharmacy of a
179 request from another pharmacy to fill or refill a prescription drug order or to perform
180 processing functions such as dispensing, drug utilization review, claims adjudication, refill

181 authorizations, and therapeutic interventions.

182 (10) "Class A pharmacy" means a pharmacy located in Utah that is authorized as a
183 retail pharmacy to compound or dispense a drug or dispense a device to the public under a
184 prescription order.

185 (11) "Class B pharmacy":

186 (a) means a pharmacy located in Utah:

187 (i) that is authorized to provide pharmaceutical care for patients in an institutional
188 setting; and

189 (ii) whose primary purpose is to provide a physical environment for patients to obtain
190 health care services; and

191 (b) (i) includes closed-door, hospital, clinic, nuclear, and branch pharmacies; and

192 (ii) pharmaceutical administration and sterile product preparation facilities.

193 (12) "Class C pharmacy" means a pharmacy that engages in the manufacture,
194 production, wholesale, or distribution of drugs or devices in Utah.

195 (13) "Class D pharmacy" means a nonresident pharmacy.

196 (14) "Class E pharmacy" means all other pharmacies.

197 (15) "Closed-door pharmacy" means a pharmacy that provides pharmaceutical care to a
198 defined and exclusive group of patients who have access to the services of the pharmacy
199 because they are treated by or have an affiliation with a specific entity, including a health
200 maintenance organization or an infusion company, but not including a hospital pharmacy, a
201 retailer of goods to the general public, or the office of a practitioner.

202 (16) "Collaborative pharmacy practice" means a practice of pharmacy whereby one or
203 more pharmacists have jointly agreed, on a voluntary basis, to work in conjunction with one or
204 more practitioners under protocol whereby the pharmacist may perform certain pharmaceutical
205 care functions authorized by the practitioner or practitioners under certain specified conditions
206 or limitations.

207 (17) "Collaborative pharmacy practice agreement" means a written and signed
208 agreement between one or more pharmacists and one or more practitioners that provides for
209 collaborative pharmacy practice for the purpose of drug therapy management of patients and
210 prevention of disease of human subjects.

211 (18) (a) "Compounding" means the preparation, mixing, assembling, packaging, or

212 labeling of a limited quantity drug, sterile product, or device:

213 (i) as the result of a practitioner's prescription order or initiative based on the
214 practitioner, patient, or pharmacist relationship in the course of professional practice;

215 (ii) for the purpose of, or as an incident to, research, teaching, or chemical analysis and
216 not for sale or dispensing; or

217 (iii) in anticipation of prescription drug orders based on routine, regularly observed
218 prescribing patterns.

219 (b) "Compounding" does not include:

220 (i) the preparation of prescription drugs by a pharmacist or pharmacy intern for sale to
221 another pharmacist or pharmaceutical facility;

222 (ii) the preparation by a pharmacist or pharmacy intern of any prescription drug in a
223 dosage form which is regularly and commonly available from a manufacturer in quantities and
224 strengths prescribed by a practitioner; or

225 (iii) the preparation of a prescription drug, sterile product, or device which has been
226 withdrawn from the market for safety reasons.

227 (19) "Confidential information" has the same meaning as "protected health
228 information" under the Standards for Privacy of Individually Identifiable Health Information,
229 45 C.F.R. Parts 160 and 164.

230 (20) "Controlled substance" means the same as that term is defined in Section [58-37-2](#).

231 (21) "Dietary supplement" has the same meaning as Public Law Title 103, Chapter
232 417, Sec. 3a(ff) which is incorporated by reference.

233 (22) "Dispense" means the interpretation, evaluation, and implementation of a
234 prescription drug order or device or nonprescription drug or device under a lawful order of a
235 practitioner in a suitable container appropriately labeled for subsequent administration to or use
236 by a patient, research subject, or an animal.

237 (23) "Dispensing medical practitioner" means an individual who is:

238 (a) currently licensed as:

239 (i) a physician and surgeon under Chapter 67, Utah Medical Practice Act;

240 (ii) an osteopathic physician and surgeon under Chapter 68, Utah Osteopathic Medical
241 Practice Act;

242 (iii) a physician assistant under Chapter 70a, Physician Assistant Act;

- 243 (iv) a nurse practitioner under Chapter 31b, Nurse Practice Act; or
244 (v) an optometrist under Chapter 16a, Utah Optometry Practice Act, if the optometrist
245 is acting within the scope of practice for an optometrist; and
246 (b) licensed by the division under the Pharmacy Practice Act to engage in the practice
247 of a dispensing medical practitioner.
- 248 (24) "Dispensing medical practitioner clinic pharmacy" means a closed-door pharmacy
249 located within a licensed dispensing medical practitioner's place of practice.
- 250 (25) "Distribute" means to deliver a drug or device other than by administering or
251 dispensing.
- 252 (26) (a) "Drug" means:
- 253 (i) a substance recognized in the official United States Pharmacopoeia, official
254 Homeopathic Pharmacopoeia of the United States, or official National Formulary, or any
255 supplement to any of them, intended for use in the diagnosis, cure, mitigation, treatment, or
256 prevention of disease in humans or animals;
- 257 (ii) a substance that is required by any applicable federal or state law or rule to be
258 dispensed by prescription only or is restricted to administration by practitioners only;
- 259 (iii) a substance other than food intended to affect the structure or any function of the
260 body of humans or other animals; and
- 261 (iv) substances intended for use as a component of any substance specified in
262 Subsections (26)(a)(i), (ii), (iii), and (iv).
- 263 (b) "Drug" does not include dietary supplements.
- 264 (27) "Drug regimen review" includes the following activities:
- 265 (a) evaluation of the prescription drug order and patient record for:
- 266 (i) known allergies;
- 267 (ii) rational therapy-contraindications;
- 268 (iii) reasonable dose and route of administration; and
- 269 (iv) reasonable directions for use;
- 270 (b) evaluation of the prescription drug order and patient record for duplication of
271 therapy;
- 272 (c) evaluation of the prescription drug order and patient record for the following
273 interactions:

- 274 (i) drug-drug;
275 (ii) drug-food;
276 (iii) drug-disease; and
277 (iv) adverse drug reactions; and
278 (d) evaluation of the prescription drug order and patient record for proper utilization,
279 including over- or under-utilization, and optimum therapeutic outcomes.

280 (28) "Drug sample" means a prescription drug packaged in small quantities consistent
281 with limited dosage therapy of the particular drug, which is marked "sample", is not intended to
282 be sold, and is intended to be provided to practitioners for the immediate needs of patients for
283 trial purposes or to provide the drug to the patient until a prescription can be filled by the
284 patient.

285 (29) "Electronic signature" means a trusted, verifiable, and secure electronic sound,
286 symbol, or process attached to or logically associated with a record and executed or adopted by
287 a person with the intent to sign the record.

288 (30) "Electronic transmission" means transmission of information in electronic form or
289 the transmission of the exact visual image of a document by way of electronic equipment.

290 (31) "Hospital pharmacy" means a pharmacy providing pharmaceutical care to
291 inpatients of a general acute hospital or specialty hospital licensed by the Department of Health
292 under Title 26, Chapter 21, Health Care Facility Licensing and Inspection Act.

293 (32) "Legend drug" has the same meaning as prescription drug.

294 (33) "Licensed pharmacy technician" means an individual licensed with the division,
295 that may, under the supervision of a pharmacist, perform the activities involved in the
296 technician practice of pharmacy.

297 (34) "Manufacturer" means a person or business physically located in Utah licensed to
298 be engaged in the manufacturing of drugs or devices.

299 (35) (a) "Manufacturing" means:

- 300 (i) the production, preparation, propagation, conversion, or processing of a drug or
301 device, either directly or indirectly, by extraction from substances of natural origin or
302 independently by means of chemical or biological synthesis, or by a combination of extraction
303 and chemical synthesis, and includes any packaging or repackaging of the substance or labeling
304 or relabeling of its container; and

305 (ii) the promotion and marketing of such drugs or devices.

306 (b) "Manufacturing" includes the preparation and promotion of commercially available
307 products from bulk compounds for resale by pharmacies, practitioners, or other persons.

308 (c) "Manufacturing" does not include the preparation or compounding of a drug by a
309 pharmacist, pharmacy intern, or practitioner for that individual's own use or the preparation,
310 compounding, packaging, labeling of a drug, or incident to research, teaching, or chemical
311 analysis.

312 (36) "Medical order" means a lawful order of a practitioner which may include a
313 prescription drug order.

314 (37) "Medication profile" or "profile" means a record system maintained as to drugs or
315 devices prescribed for a pharmacy patient to enable a pharmacist or pharmacy intern to analyze
316 the profile to provide pharmaceutical care.

317 (38) "Misbranded drug or device" means a drug or device considered misbranded under
318 21 U.S.C. Sec. 352 (2003).

319 (39) (a) "Nonprescription drug" means a drug which:

320 (i) may be sold without a prescription; and

321 (ii) is labeled for use by the consumer in accordance with federal law.

322 (b) "Nonprescription drug" includes homeopathic remedies.

323 (40) "Nonresident pharmacy" means a pharmacy located outside of Utah that sells to a
324 person in Utah.

325 (41) "Nuclear pharmacy" means a pharmacy providing radio-pharmaceutical service.

326 (42) "Out-of-state mail service pharmacy" means a pharmaceutical facility located
327 outside the state that is licensed and in good standing in another state, that:

328 (a) ships, mails, or delivers by any lawful means a dispensed legend drug to a patient in
329 this state pursuant to a lawfully issued prescription;

330 (b) provides information to a patient in this state on drugs or devices which may
331 include, but is not limited to, advice relating to therapeutic values, potential hazards, and uses;
332 or

333 (c) counsels pharmacy patients residing in this state concerning adverse and therapeutic
334 effects of drugs.

335 (43) "Patient counseling" means the written and oral communication by the pharmacist

336 or pharmacy intern of information, to the patient or caregiver, in order to ensure proper use of
337 drugs, devices, and dietary supplements.

338 (44) "Pharmaceutical administration facility" means a facility, agency, or institution in
339 which:

340 (a) prescription drugs or devices are held, stored, or are otherwise under the control of
341 the facility or agency for administration to patients of that facility or agency;

342 (b) prescription drugs are dispensed to the facility or agency by a licensed pharmacist
343 or pharmacy intern with whom the facility has established a prescription drug supervising
344 relationship under which the pharmacist or pharmacy intern provides counseling to the facility
345 or agency staff as required, and oversees drug control, accounting, and destruction; and

346 (c) prescription drugs are professionally administered in accordance with the order of a
347 practitioner by an employee or agent of the facility or agency.

348 (45) (a) "Pharmaceutical care" means carrying out the following in collaboration with a
349 prescribing practitioner, and in accordance with division rule:

350 (i) designing, implementing, and monitoring a therapeutic drug plan intended to
351 achieve favorable outcomes related to a specific patient for the purpose of curing or preventing
352 the patient's disease;

353 (ii) eliminating or reducing a patient's symptoms; or

354 (iii) arresting or slowing a disease process.

355 (b) "Pharmaceutical care" does not include prescribing of drugs without consent of a
356 prescribing practitioner.

357 (46) "Pharmaceutical facility" means a business engaged in the dispensing, delivering,
358 distributing, manufacturing, or wholesaling of prescription drugs or devices within or into this
359 state.

360 (47) (a) "Pharmaceutical wholesaler or distributor" means a pharmaceutical facility
361 engaged in the business of wholesale vending or selling of a prescription drug or device to
362 other than a consumer or user of the prescription drug or device that the pharmaceutical facility
363 has not produced, manufactured, compounded, or dispensed.

364 (b) "Pharmaceutical wholesaler or distributor" does not include a pharmaceutical
365 facility carrying out the following business activities:

366 (i) intracompany sales;

367 (ii) the sale, purchase, or trade of a prescription drug or device, or an offer to sell,
368 purchase, or trade a prescription drug or device, if the activity is carried out between one or
369 more of the following entities under common ownership or common administrative control, as
370 defined by division rule:

371 (A) hospitals;

372 (B) pharmacies;

373 (C) chain pharmacy warehouses, as defined by division rule; or

374 (D) other health care entities, as defined by division rule;

375 (iii) the sale, purchase, or trade of a prescription drug or device, or an offer to sell,
376 purchase, or trade a prescription drug or device, for emergency medical reasons, including
377 supplying another pharmaceutical facility with a limited quantity of a drug, if:

378 (A) the facility is unable to obtain the drug through a normal distribution channel in
379 sufficient time to eliminate the risk of harm to a patient that would result from a delay in
380 obtaining the drug; and

381 (B) the quantity of the drug does not exceed an amount reasonably required for
382 immediate dispensing to eliminate the risk of harm;

383 (iv) the distribution of a prescription drug or device as a sample by representatives of a
384 manufacturer; and

385 (v) the distribution of prescription drugs, if:

386 (A) the facility's total distribution-related sales of prescription drugs does not exceed
387 5% of the facility's total prescription drug sales; and

388 (B) the distribution otherwise complies with 21 C.F.R. Sec. 1307.11.

389 (48) "Pharmacist" means an individual licensed by this state to engage in the practice
390 of pharmacy.

391 (49) "Pharmacist-in-charge" means a pharmacist currently licensed in good standing
392 who accepts responsibility for the operation of a pharmacy in conformance with all laws and
393 rules pertinent to the practice of pharmacy and the distribution of drugs, and who is personally
394 in full and actual charge of the pharmacy and all personnel.

395 (50) "Pharmacist preceptor" means a licensed pharmacist in good standing with one or
396 more years of licensed experience. The preceptor serves as a teacher, example of professional
397 conduct, and supervisor of interns in the professional practice of pharmacy.

398 (51) "Pharmacy" means any place where:

399 (a) drugs are dispensed;

400 (b) pharmaceutical care is provided;

401 (c) drugs are processed or handled for eventual use by a patient; or

402 (d) drugs are used for the purpose of analysis or research.

403 (52) "Pharmacy benefits manager or coordinator" means a person or entity that
404 provides a pharmacy [~~benefit~~] benefits management [~~services~~] service as defined in Section
405 49-20-502 on behalf of a self-insured employer, insurance company, health maintenance
406 organization, or other plan sponsor, as defined by rule.

407 (53) "Pharmacy intern" means an individual licensed by this state to engage in practice
408 as a pharmacy intern.

409 (54) "Pharmacy technician training program" means an approved technician training
410 program providing education for pharmacy technicians.

411 (55) (a) "Practice as a dispensing medical practitioner" means the practice of pharmacy,
412 specifically relating to the dispensing of a prescription drug in accordance with Part 8,
413 Dispensing Medical Practitioner and Dispensing Medical Practitioner Clinic Pharmacy, and
414 division rule adopted after consultation with the Board of pharmacy and the governing boards
415 of the practitioners described in Subsection (23)(a).

416 (b) "Practice as a dispensing medical practitioner" does not include:

417 (i) using a vending type of dispenser as defined by the division by administrative rule;

418 or

419 (ii) except as permitted by Section 58-17b-805, dispensing of a controlled substance as
420 defined in Section 58-37-2.

421 (56) (a) "Practice as a licensed pharmacy technician" means engaging in practice as a
422 pharmacy technician under the general supervision of a licensed pharmacist and in accordance
423 with a scope of practice defined by division rule made in collaboration with the board.

424 (b) "Practice as a licensed pharmacy technician" does not include:

425 (i) performing a drug utilization review, prescription drug order clarification from a
426 prescriber, final review of the prescription, dispensing of the drug, or counseling a patient with
427 respect to a prescription drug;

428 (ii) except as permitted by rules made by the division in consultation with the board,

- 429 final review of a prescribed drug prepared for dispensing;
- 430 (iii) counseling regarding nonprescription drugs and dietary supplements unless
- 431 delegated by the supervising pharmacist; or
- 432 (iv) receiving new prescription drug orders when communicating telephonically or
- 433 electronically unless the original information is recorded so the pharmacist may review the
- 434 prescription drug order as transmitted.
- 435 (57) "Practice of pharmacy" includes the following:
- 436 (a) providing pharmaceutical care;
- 437 (b) collaborative pharmacy practice in accordance with a collaborative pharmacy
- 438 practice agreement;
- 439 (c) compounding, packaging, labeling, dispensing, administering, and the coincident
- 440 distribution of prescription drugs or devices, provided that the administration of a prescription
- 441 drug or device is:
- 442 (i) pursuant to a lawful order of a practitioner when one is required by law; and
- 443 (ii) in accordance with written guidelines or protocols:
- 444 (A) established by the licensed facility in which the prescription drug or device is to be
- 445 administered on an inpatient basis; or
- 446 (B) approved by the division, in collaboration with the board and the Physicians
- 447 Licensing Board, created in Section [58-67-201](#), if the prescription drug or device is to be
- 448 administered on an outpatient basis solely by a licensed pharmacist;
- 449 (d) participating in drug utilization review;
- 450 (e) ensuring proper and safe storage of drugs and devices;
- 451 (f) maintaining records of drugs and devices in accordance with state and federal law
- 452 and the standards and ethics of the profession;
- 453 (g) providing information on drugs or devices, which may include advice relating to
- 454 therapeutic values, potential hazards, and uses;
- 455 (h) providing drug product equivalents;
- 456 (i) supervising pharmacist's supportive personnel, pharmacy interns, and pharmacy
- 457 technicians;
- 458 (j) providing patient counseling, including adverse and therapeutic effects of drugs;
- 459 (k) providing emergency refills as defined by rule;

- 460 (l) telepharmacy; [~~and~~]
- 461 (m) formulary management intervention[-]; and
- 462 (n) prescribing and dispensing a self-administered hormonal contraceptive in
- 463 accordance with Title 26, Chapter 62, Family Planning Access Act.

464 (58) "Practice of telepharmacy" means the practice of pharmacy through the use of
465 telecommunications and information technologies.

466 (59) "Practice of telepharmacy across state lines" means the practice of pharmacy
467 through the use of telecommunications and information technologies that occurs when the
468 patient is physically located within one jurisdiction and the pharmacist is located in another
469 jurisdiction.

470 (60) "Practitioner" means an individual currently licensed, registered, or otherwise
471 authorized by the appropriate jurisdiction to prescribe and administer drugs in the course of
472 professional practice.

473 (61) "Prescribe" means to issue a prescription:

474 (a) orally or in writing; or

475 (b) by telephone, facsimile transmission, computer, or other electronic means of
476 communication as defined by division rule.

477 (62) "Prescription" means an order issued:

478 (a) by a licensed practitioner in the course of that practitioner's professional practice or
479 by collaborative pharmacy practice agreement; and

480 (b) for a controlled substance or other prescription drug or device for use by a patient
481 or an animal.

482 (63) "Prescription device" means an instrument, apparatus, implement, machine,
483 contrivance, implant, in vitro reagent, or other similar or related article, and any component
484 part or accessory, which is required under federal or state law to be prescribed by a practitioner
485 and dispensed by or through a person or entity licensed under this chapter or exempt from
486 licensure under this chapter.

487 (64) "Prescription drug" means a drug that is required by federal or state law or rule to
488 be dispensed only by prescription or is restricted to administration only by practitioners.

489 (65) "Repackage":

490 (a) means changing the container, wrapper, or labeling to further the distribution of a

491 prescription drug; and

492 (b) does not include:

493 (i) Subsection (65)(a) when completed by the pharmacist responsible for dispensing the
494 product to a patient; or

495 (ii) changing or altering a label as necessary for a dispensing practitioner under Part 8,
496 Dispensing Medical Practitioner and Dispensing Medical Practitioner Clinic Pharmacy, for
497 dispensing a product to a patient.

498 (66) "Research using pharmaceuticals" means research:

499 (a) conducted in a research facility, as defined by division rule, that is associated with a
500 university or college in the state accredited by the Northwest Commission on Colleges and
501 Universities;

502 (b) requiring the use of a controlled substance, prescription drug, or prescription
503 device;

504 (c) that uses the controlled substance, prescription drug, or prescription device in
505 accordance with standard research protocols and techniques, including, if required, those
506 approved by an institutional review committee; and

507 (d) that includes any documentation required for the conduct of the research and the
508 handling of the controlled substance, prescription drug, or prescription device.

509 (67) "Retail pharmacy" means a pharmaceutical facility dispensing prescription drugs
510 and devices to the general public.

511 (68) (a) "Self-administered hormonal contraceptive" means a self-administered
512 hormonal contraceptive that is approved by the United States Food and Drug Administration to
513 prevent pregnancy.

514 (b) "Self-administered hormonal contraceptive" includes an oral hormonal
515 contraceptive, a hormonal vaginal ring, and a hormonal contraceptive patch.

516 (c) "Self-administered hormonal contraceptive" does not include any drug intended to
517 induce an abortion, as that term is defined in Section [76-7-301](#).

518 [~~68~~] (69) "Self-audit" means an internal evaluation of a pharmacy to determine
519 compliance with this chapter.

520 [~~69~~] (70) "Supervising pharmacist" means a pharmacist who is overseeing the
521 operation of the pharmacy during a given day or shift.

522 [~~(70)~~] (71) "Supportive personnel" means unlicensed individuals who:

523 (a) may assist a pharmacist, pharmacist preceptor, pharmacy intern, or licensed
524 pharmacy technician in nonjudgmental duties not included in the definition of the practice of
525 pharmacy, practice of a pharmacy intern, or practice of a licensed pharmacy technician, and as
526 those duties may be further defined by division rule adopted in collaboration with the board;
527 and

528 (b) are supervised by a pharmacist in accordance with rules adopted by the division in
529 collaboration with the board.

530 [~~(71)~~] (72) "Unlawful conduct" means the same as that term is defined in Sections
531 58-1-501 and 58-17b-501.

532 [~~(72)~~] (73) "Unprofessional conduct" means the same as that term is defined in
533 Sections 58-1-501 and 58-17b-502 and may be further defined by rule.

534 [~~(73)~~] (74) "Veterinary pharmaceutical facility" means a pharmaceutical facility that
535 dispenses drugs intended for use by animals or for sale to veterinarians for the administration
536 for animals.

537 Section 9. Section 58-17b-501 is amended to read:

538 **58-17b-501. Unlawful conduct.**

539 "Unlawful conduct" includes:

540 (1) knowingly preventing or refusing to permit an authorized agent of the division to
541 conduct an inspection pursuant to Section 58-17b-103;

542 (2) failing to deliver the license, permit, or certificate to the division upon demand, if it
543 has been revoked, suspended, or refused;

544 (3) (a) using the title "pharmacist," "druggist," "pharmacy intern," "pharmacy
545 technician," or a term having similar meaning, except by a person licensed as a pharmacist,
546 pharmacy intern, or pharmacy technician; or

547 (b) conducting or transacting business under a name that contains, as part of that name,
548 the words "drugstore," "pharmacy," "drugs," "medicine store," "medicines," "drug shop,"
549 "apothecary," "prescriptions," or a term having a similar meaning, or in any manner
550 advertising, otherwise describing, or referring to the place of the conducted business or
551 profession, unless the place is a pharmacy issued a license by the division, except an
552 establishment selling nonprescription drugs and supplies may display signs bearing the words

553 "packaged drugs," "drug sundries," or "nonprescription drugs," and is not considered to be a
554 pharmacy or drugstore by reason of the display;

555 (4) buying, selling, causing to be sold, or offering for sale, a drug or device that bears,
556 or the package bears or originally did bear, the inscription "sample," "not for resale," "for
557 investigational or experimental use only," or other similar words, except when a cost is
558 incurred in the bona fide acquisition of an investigational or experimental drug;

559 (5) using to a person's own advantages or revealing to anyone other than the division,
560 board, and its authorized representatives, or to the courts, when relevant to a judicial or
561 administrative proceeding under this chapter, information acquired under authority of this
562 chapter or concerning a method of process that is a trade secret;

563 (6) procuring or attempting to procure a drug or to have someone else procure or
564 attempt to procure a drug:

565 (a) by fraud, deceit, misrepresentation, or subterfuge;

566 (b) by forgery or alteration of a prescription or a written order;

567 (c) by concealment of a material fact;

568 (d) by use of a false statement in a prescription, chart, order, or report; or

569 (e) by theft;

570 (7) filling, refilling, or advertising the filling or refilling of prescriptions for a
571 consumer or patient residing in this state if the person is not licensed:

572 (a) under this chapter; or

573 (b) in the state from which he is dispensing;

574 (8) requiring an employed pharmacist, pharmacy intern, pharmacy technician, or
575 authorized supportive personnel to engage in conduct in violation of this chapter;

576 (9) being in possession of a prescription drug for an unlawful purpose;

577 (10) dispensing a prescription drug to a person who does not have a prescription from a
578 practitioner, except as permitted under:

579 (a) Title 26, Chapter 55, Opiate Overdose Response Act; or

580 (b) Title 26, Chapter 62, Family Planning Access Act.

581 (11) dispensing a prescription drug to a person who the person dispensing the drug
582 knows or should know is attempting to obtain drugs by fraud or misrepresentation;

583 [(H)] (12) selling, dispensing, distributing, or otherwise trafficking in prescription

584 drugs when not licensed to do so or when not exempted from licensure; and
585 ~~[(12)]~~ (13) a person using a prescription drug or controlled substance that was not
586 lawfully prescribed for the person by a practitioner.

587 Section 10. Section **58-17b-502** is amended to read:

588 **58-17b-502. Unprofessional conduct.**

589 "Unprofessional conduct" includes:

590 (1) willfully deceiving or attempting to deceive the division, the board, or their agents
591 as to any relevant matter regarding compliance under this chapter;

592 (2) (a) except as provided in Subsection (2)(b):

593 (i) paying or offering rebates to practitioners or any other health care providers, or
594 receiving or soliciting rebates from practitioners or any other health care provider; or

595 (ii) paying, offering, receiving, or soliciting compensation in the form of a commission,
596 bonus, rebate, kickback, or split fee arrangement with practitioners or any other health care
597 provider, for the purpose of obtaining referrals.

598 (b) Subsection (2)(a) does not apply to:

599 (i) giving or receiving price discounts based on purchase volume;

600 (ii) passing along pharmaceutical manufacturer's rebates; or

601 (iii) providing compensation for services to a veterinarian.

602 (3) misbranding or adulteration of any drug or device or the sale, distribution, or
603 dispensing of any outdated, misbranded, or adulterated drug or device;

604 (4) engaging in the sale or purchase of drugs or devices that are samples or packages
605 bearing the inscription "sample" or "not for resale" or similar words or phrases;

606 (5) except as provided in Section **58-17b-503** or Part 9, Charitable Prescription Drug
607 Recycling Act, accepting back and redistributing any unused drug, or a part of it, after it has
608 left the premises of any pharmacy, unless the drug is in a unit pack, as defined in Section
609 **58-17b-503**, or the manufacturer's sealed container, as defined in rule;

610 (6) an act in violation of this chapter committed by a person for any form of
611 compensation if the act is incidental to the person's professional activities, including the
612 activities of a pharmacist, pharmacy intern, or pharmacy technician;

613 (7) violating ~~[Federal Title II, P.L. 91, Controlled Substances Act,];~~

614 (a) the federal Controlled Substances Act, Title II, P.L. 91-513;

- 615 **(b)** Title 58, Chapter 37, Utah Controlled Substances Act[-]; or
616 **(c)** rules or regulations adopted under either act;
- 617 **(8)** requiring or permitting pharmacy interns or technicians to engage in activities
618 outside the scope of practice for their respective license classifications, as defined in this
619 chapter and division rules made in collaboration with the board, or beyond their scope of
620 training and ability;
- 621 **(9)** administering:
- 622 **(a)** without appropriate training, as defined by rule;
- 623 **(b)** without a physician's order, when one is required by law; and
- 624 **(c)** in conflict with a practitioner's written guidelines or written protocol for
625 administering;
- 626 **(10)** disclosing confidential patient information in violation of the provisions of the
627 Health Insurance Portability and Accountability Act of 1996, Pub. L. No. 104-191, 110 Stat.
628 1936, as amended, or other applicable law;
- 629 **(11)** engaging in the practice of pharmacy without a licensed pharmacist designated as
630 the pharmacist-in-charge;
- 631 **(12)** failing to report to the division any adverse action taken by another licensing
632 jurisdiction, government agency, law enforcement agency, or court for conduct that in
633 substance would be considered unprofessional conduct under this section; [~~and~~]
- 634 **(13)** as a pharmacist or pharmacy intern, compounding a prescription drug in a dosage
635 form which is regularly and commonly available from a manufacturer in quantities and
636 strengths prescribed by a practitioner[-]; and
- 637 **(14)** failing to act in accordance with Title 26, Chapter 62, Family Planning Access
638 Act, when dispensing a self-administered hormonal contraceptive under a standing order.